Monoclonal antibodies were ‘doing nothing’ against omicron. That’s why FDA pulled its authorization.

Monoclonal antibodies were ‘doing nothing’ against omicron. That’s why FDA pulled its authorization.

This post was originally published on this siteMonoclonal antibodies from drug-makers Regeneron and Eli Lilly have proven ineffective against the omicron variant of COVID-19.     

Read more